MSLN and neoplasm: MPM is strongly responsive to synthetic activators of cGAS/STING pathway that increase the production of CXCR3 in tumor cells and cancer-associated fibroblasts, resulting in the recruitment and activation of NK cells and mesothelin-targeted chimeric antigen receptor (CAR)-NK cells [45].